[筑波大学新设施的质子束治疗初步经验]
[Initial experience of proton beam therapy at the new facility of the University of Tsukuba].
作者信息
Kagei Kenji, Tokuuye Koichi, Sugahara Shinji, Hata Masaharu, Igaki Hiroshi, Hashimoto Takayuki, Ohara Kiyoshi, Akine Yasuyuki
机构信息
Proton Medical Research Center, Department of Radiation Oncology, University Hospital, University of Tsukuba.
出版信息
Nihon Igaku Hoshasen Gakkai Zasshi. 2004 May;64(4):225-30.
PURPOSE
To present the initial experience with proton beam therapy at the new Proton Medical Research Center (PMRC) of the University of Tsukuba.
MATERIALS AND METHODS
The new facility has a synchrotron with maximum energy of 250MeV and two rotational gantries. We treated 105 patients with 120 lesions with proton beams in the first year, beginning in September 2001. The most common lesion treated was primary liver cancer (40 lesions) followed by lung cancer, head and neck cancers, and prostate cancer. Concurrent X-ray radiotherapy was given for 38 of the 120 lesions.
RESULTS
The median follow-up period was 11 months (range, 1-19 months). Of the 105 patients, 97% had Grade 0-2 RTOG/EORTC acute morbidities, while the remaining 3% had Grade 3. Tumor response after irradiation was CR for 35% of the lesions, PR for 25%, SD for 22%, PD for 9%, and not evaluated for 9%.
CONCLUSION
The proton beam therapy conducted at the new facility of the University of Tsukuba was safe and effective.
目的
介绍筑波大学新质子医学研究中心（PMRC）质子束治疗的初步经验。
材料与方法
新设施有一台最大能量为250MeV的同步加速器和两个旋转机架。从2001年9月开始，我们在第一年用质子束治疗了105例患者的120个病灶。治疗的最常见病灶是原发性肝癌（40个病灶），其次是肺癌、头颈癌和前列腺癌。120个病灶中有38个同时接受了X线放射治疗。
结果
中位随访期为11个月（范围1 - 19个月）。105例患者中，97%发生0 - 2级RTOG/EORTC急性不良反应，其余3%为3级。照射后肿瘤反应为完全缓解（CR）的病灶占35%，部分缓解（PR）占25%，疾病稳定（SD）占22%，疾病进展（PD）占9%，未评估占9%。
结论
筑波大学新设施进行的质子束治疗安全有效。
Zotero 插件